Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who may pay to be displayed in certain positions on certain pages, or may compensate us for referring users to their services. While our reviews and assessments of each product are independent and unbiased, the order in which brands are presented and the placement of offers may be impacted and some of the links on this page may be affiliate links from which we earn a commission. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >
5 Best Cannabis Stocks to Buy for Q4 2025
Trade your favourite markets with our top-rated broker, .
CFD service. 82% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.
This information is NOT relevant to EU residents who are to be serviced by EU subsidiaries of the Plus500 Group, such as Plus500CY Ltd, authorised by CySEC (Reg. 250/14). Different regulatory requirements apply in Europe such as leverage limitations and bonus restrictions.
The cannabis industry has gone through a rollercoaster in the past few years. It initially started with enthusiasm after more states started legalizing the product. At its peak, most cannabis companies were worth billions of dollars as multiple reports highlighted the total addressable market.
Recently, however, most cannabis stocks have tumbled amid rising competition and regulatory hurdles. For example, most mainstream banks have avoided cannabis because it is a Schedule 1 drug by the DEA. These banks have always been concerned about unintended consequences like money laundering claims.
There is hope that the DEA will reclassify cannabis to schedule 3 drug, thereby loosening restrictions that exist to date. Such a move will be a boon to most cannabis companies like Tilray Brands, Aurora Cannabis, and Curaleaf.
What are the top weed stocks to buy?
Copy link to sectionThe best stocks are listed in the table below. You can follow the links to find their up to date price information or scroll down for more information on why each one was chosen.
| # | Stock symbol | Company name | Learn more |
|---|---|---|---|
| 1 | CGC | Canopy Growth Corporation | Learn more > |
| 2 | TLRY | Tilray Inc. | Learn more > |
| 3 | CRON | Cronos Group Inc. | Learn more > |
| 4 | ACB | Aurora Cannabis Inc. | Learn more > |
| 5 | CURLF | Curaleaf Holdings | Learn more > |
1. Canopy Growth Corp (NYSE: CGC)
Copy link to section- Market cap: $544 million
- Dividend yield: N/A
- 1-year return: -2.73%
- Country: US
Canopy Growth is a Canadian cannabis company and the largest weed stock in the world by market cap. Founded in 2013, it was the first public cannabis company in North America when it began selling shares on the Toronto Stock Exchange in 2018.
CGC’s stock price performance is indicative of the industry as a whole, with most of the activity coming over the last couple of years. It has regularly seen more than 100% growth in a short period of time, with similarly dramatic falls along the way. That’s often a reflection of the rising and falling hopes of cannabis being legalised by the federal government in the US.
Canopy Growth, like other cannabis companies, has not done well in the past few years as concerns about the industry remained. It slumped from an all-time high of almost $500 to below $10 today.
The company’s growth has not been impressive as its total revenue dropped from over $408 million in 2022 to $219 million in 2023. It has also made losses worth billions of dollars in the past few years and diluted its shareholders.
However, Canopy Growth seems like a good contrarian buy as it is set to benefit from the reclassification in the US. It has also become a cheap company that has room to grow in the coming years.
2. Tilray Inc. (NASDAQ: TLRY)
Copy link to section- Market cap: $1.46 billion
- Dividend yield: N/A
- 1-year return: 2.43%
- Country: Canada
Canada is a good cannabis stock for three main reasons. First, it has diversified its business to the alcoholic drinks business. In 2023, it boosted this division by buying several beer brands from AB InBev. The benefit is that this division will help to provide stability and more revenue sources.
Second, the company has done well over the years even though it has a minimal presence in the United States. The management expects that it will gain more market share if it launches its business in the US after more regulatory clarity. It has also expanded its business in Germany, a country that recently passed friendly cannabis regulations.
Third, Tilray Brands has room to become profitable. It s revenue has jumped from over $179 million in 2019 to over $627 million in 2023. While losses have surged, the company has vowed to reduce its costs and focus on boosting its profitability.
All these factors could help the Tilray Brands stock rebound. It has crashed to a low of $1.77 from its all-time high of over $60.
3. Cronos Group Inc. (NASDAQ: CRON)
Copy link to section- Market cap: $939 million
- Dividend yield: N/A
- 1-year return: 40%
- Country: Canada
Cronos Group, a Canadian company, has become one of the best-performing cannabis stocks in the industry. It has soared by over 40% in the past 12 months, beating most of its peers.
This growth happened as its revenue jumped from over $23.8 million in 2019 to over $87.2 million in 2023. Most importantly, the company has been trimming its losses. After peaking at $396 million in 2021, its total loss has narrowed to over $57 million and the management expects this trend to continue.
Cronos Group also has a solid balance sheet, meaning that it may not need to raise additional cash soon. It has over $855 million in cash and short-term investments and zero debt. This means that it has the cash it needs to fund acquisitions and growth.
Therefore, with Cronos, we have a company whose revenue is growing, has a solid balance sheet, and is narrowing its losses, making it a good investment.
4. Aurora Cannabis Inc. (NYSE: ACB)
Copy link to section- Market cap: $310 million
- Dividend yield: N/A
- 1-year return: 5.97%
- Country: Cannabis
Aurora Cannabis is another Canadian company in the cannabis industry. It offers solutions in the medical marijuana and for adult use across its several brands like Drift, Daily Special, MedReleaf, and Greybeard.
Like other cannabis companies, Aurora is a fallen angel as its stock plummeted from almost $800 to less than $10. This plunge happened as its revenue growth plummeted and its losses mounted.
Total revenue peaked at $197.9 million in 2020 and slowed to over $172 million in 2023. At the same time, the company’s net loss has totaled over $4 billion in the past five years, which has forced it to be highly dilutive.
Aurora Cannabis is a high-risk and high-reward cannabis company to invest in. The stock could double if it resumes its growth path. The risk is that it could need to raise additional cash in the next two years since its cash reserves are falling.
5. Curaleaf Holdings (OTCQX: CURLF)
Copy link to section- Market cap: $3.3 billion
- Dividend yield: N/A
- 1-year return: 49%
- Country: Canada
Curaleaf Holdings is one of the fastest-growing companies in the cannabis industry. Its annual revenue has jumped from over $221 million in 2019 million to over $1.34 billion in 2023. This growth, however, has come at a cost as its annual losses have jumped over the years.
However, the company has committed to start focusing on profits instead of market share, a move that could see it become profitable. The other challenge is that its balance sheet is not all that good as the company has just $105 million in cash and almost $500 million in debt.
Therefore, the main reason to invest in Curaleaf is that it could benefit from relaxed US rules and the upcoming reclassification. It also has a solid market share that is continuing to grow.
Where to buy the best weed shares
Copy link to sectionUse any of the platforms below to start trading straight away. You can use the links in the table to go ahead and create an account, or look through our reviews for help in choosing one.
Plus500
CFD service. 82% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.
This information is NOT relevant to EU residents who are to be serviced by EU subsidiaries of the Plus500 Group, such as Plus500CY Ltd, authorised by CySEC (Reg. 250/14). Different regulatory requirements apply in Europe such as leverage limitations and bonus restrictions.
51% of retail CFD accounts lose money. Your capital is at risk.
What is a weed stock?
Copy link to sectionA company that’s involved in the production or sale of cannabis. That might mean owning the farms that grow it, or turning the plant into a consumable good, or being the one that sells it to customers. Often companies involved in the industry do some combination of all three and their products include things like medicinal cannabis, CBD oil and hemp.
Are cannabis shares a good investment?
Copy link to sectionThey can be but they tend to be quite volatile and a lot of their potential is based on the assumption that weed will be legalised across the world. While that is happening, the pace of change can be slow and so the stocks tend to rise and fall on small nuggets of news.
What that means in practice is that they can be a good investment if you understand the risks and don’t pin all your hopes on one company. As with all portfolios, the best way to be successful is to have balance, so think about spreading your money out across a few different companies in the cannabis industry along with more traditional stocks.
As legalisation is such a crucial aspect of the market, you have to follow any new updates so that you can react accordingly. You should expect some volatility as a matter of course, but use our latest news articles to help you stay informed so that you can plan your moves accordingly.
Methodology: How we choose the best cannabis stocks
Copy link to sectionAt Invezz, our mission is to empower our readers with the most accurate and reliable financial information. Our curated selection of the best stocks in specific industries is designed to provide investors with well-researched, expertly reviewed stock recommendations. Our team follows a rigorous process to ensure our readers receive high-quality, trustworthy stock selections.
- Initial screening. Our team of experienced stock market analysts conducts an initial screening of stocks within the chosen industry. This involves analyzing a broad range of companies based on key financial metrics such as revenue growth, profitability, debt levels, and market capitalization.
- Earnings reports and financial analysis. Analysts review the latest earnings reports of shortlisted companies. This includes a detailed assessment of financial statements, looking for consistent earnings growth, strong balance sheets, and positive cash flow trends. Special attention is given to year-over-year performance and quarterly results.
- Sector analysis. A comprehensive sector analysis is conducted to understand the macroeconomic factors affecting the industry. This includes examining market trends, competitive landscape, regulatory changes, and technological advancements. Our analysts utilize industry reports, market research, and economic forecasts to gain a holistic view of the sector.
- Analyst recommendations. We consider recommendations from reputable sources such as Barron’s and Zacks. These sources provide expert opinions and ratings on stocks, which serve as an additional layer of validation for our selections. Incorporating external analyst recommendations ensures that our curated stocks are backed by a consensus of expert views.
- Internal review. After the initial selection by our analysts, the chosen stocks are reviewed by a sub-editor. The sub-editor ensures that the analysis is clear, concise, and adheres to Invezz’s editorial guidelines. This review process helps maintain the quality and readability of our content, making it accessible to a broad audience.
- Quarterly updates. To ensure our stock recommendations remain relevant and up-to-date, we update the curated section quarterly. Each update cycle involves re-evaluating the stocks based on the latest financial reports, industry developments, and market conditions. This regular update process ensures that our recommendations reflect the most current information available.
Our approach combines expert analysis, comprehensive research, and regular updates to deliver reliable and insightful investment recommendations. Read more about our review process and editorial policy.
